Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Provided By PR Newswire

Last update: Apr 15, 2025

Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in
Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-
Induced Skin Toxicities